Human and animal models of V(D)J recombination deficiency

Current Opinion in Immunology

Volumn 15, Issue 5, 2003, Pages 592-598

  De Villartay, Jean Pierre ^a   Poinsignon, Catherine ^a   De Chasseval, Regina ^a   Buck, Dietke ^a   Le Guyader, Gwenaël ^a   Villey, Isabelle ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; RAG1 PROTEIN; RAG2 PROTEIN; RECOMBINANT DNA; RECOMBINASE;

B CELL LYMPHOMA; COMBINED IMMUNODEFICIENCY; DNA RECOMBINATION; GENE; GENE MUTATION; GENE TARGETING; GENETIC CORRELATION; GENETIC RECOMBINATION; GENOMICS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOLOGY; MOUSE STRAIN; MUTATIONAL ANALYSIS; NONHUMAN; OMENN SYNDROME; RADIOSENSITIVITY; RAG1 GENE; RAG2 GENE; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 0141518299     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(03)00101-8     Document Type: Review

References (65)

1. Bassing C.H., Swat W., Alt F.W. The mechanism and regulation of chromosomal V(D)J recombination. Cell. 109:2002;S45-S55.
2. Gellert M. V(D)J recombination: rag proteins, repair factors, and regulation. Annu Rev Biochem. 71:2002;101-132.
3. Brandt V.L., Roth D.B. A recombinase diversified: new functions of the RAG proteins. Curr Opin Immunol. 14:2002;224-229.
4. Haber J.E. Partners and pathways repairing a double-strand break. Trends Genet. 16:2000;259-264.
5. de Villartay J.P. V(D)J recombination and DNA repair: lessons from human immune deficiencies and other animal models. Curr Opin Allergy Clin Immunol. 2:2002;473-479.
6. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaionnou V.E. RAG-1 deficient mice have no mature B and T lymphocytes. Cell. 68:1992;869-877.
7. Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., Alt F.W. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:1992;855-867.
8. Villa A., Sobacchi C., Notarangelo L.D., Bozzi F., Abinun M., Abrahamsen T.G., Arkwright P.D., Baniyash M., Brooks E.G., Conley M.E.et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 97:2001;81-88.
9. Fischer A. Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet. 357:2001;1863-1869.
10. Callebaut I., Mornon J.P. The V(D)J recombination activating protein RAG2 consists of a six-bladed propeller and a PHD fingerlike domain, as revealed by sequence analysis. Cell Mol Life Sci. 54:1998;880-891.
11. Corneo B., Moshous D., Callebaut I., de Chasseval R., Fischer A., de Villartay J.P. 3D clustering of human RAG2 gene mutations in Severe Combined Immune Deficiency (SCID). J Biol Chem. 275:2000;12672-12675.
12. Corneo B., Moshous D., Gungor T., Wulffrat N., Philippet P., Le Deist F., Fischer A., de Villartay J.P. Identical mutations in RAG1 and RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome. Blood. 97:2001;2772-2776.
13. Wienholds E., Schulte-Merker S., Walderich B., Plasterk R.H. Target-selected inactivation of the zebrafish rag1 gene. Science. 297:2002;99-102 This paper describes an interesting new strategy using zebrafish for the high-throughput generation and analysis of mutations in any given gene.
14. Aasland R., Gibson T.J., Stewart A.F. The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci. 20:1995;56-59.
15. Roman C.A., Cherry S.R., Baltimore D. Complementation of V(D)J recombination deficiency in RAG-1(-/-) B cells reveals a requirement for novel elements in the N-terminus of RAG-1. Immunity. 7:1997;13-24.
16. Kirch S.A., Rathbun G.A., Oettinger M.A. Dual role of RAG2 in V(D)J recombination: catalysis and regulation of ordered Ig gene assembly. EMBO J. 17:1998;4881-4886.
17. ••].
18. ••] present the generation of core-Rag2 KI models that demonstrate the fundamental role of the 'dispensable' region of Rag2 for the proper rearrangements of endogenous Ig and TCR loci.
19. Roth D.B., Craig N.L. VDJ recombination: a transposase goes to work. Cell. 94:1998;411-414.
20. Agrawal A., Eastman Q.M., Schatz D.G. Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. Nature. 394:1998;744-751.
21. Hiom K., Melek M., Gellert M. DNA transposition by the RAG1 and RAG2 proteins: a possible source of oncogenic translocations. Cell. 94:1998;463-470.
22. Melek M., Jones J.M., O'Dea M.H., Pais G., Burke T.R. Jr., Pommier Y., Neamati N., Gellert M. Effect of HIV integrase inhibitors on the RAG1/2 recombinase. Proc Natl Acad Sci USA. 99:2002;134-137 The results presented in this report provide new experimental arguments to favor the relationship between the Rag1/2 recombinase and transposases.
23. Neiditch M.B., Lee G.S., Huye L.E., Brandt V.L., Roth D.B. The V(D)J recombinase efficiently cleaves and transposes signal joints. Mol Cell. 9:2002;871-878 The ligation of signal ends does not neutralize their reactivity in transposition reaction as the SJ can be re-cleaved by Rag1/2.
24. Messier T.L., O'Neill J.P., Hou S.M., Nicklas J.A., Finette B.A. In vivo transposition mediated by V(D)J recombinase in human T lymphocytes. EMBO J. 22:2003;1381-1388 The authors present the first evidence of a possible in vivo transposition reaction mediated by Rag1/2.
25. •].
26. •] discuss the role of the carboxy-terminal part of Rag2 and a GTP-binding site of Rag1 as potentially important regions in the negative regulation of Rag1/2 transposase activity.
27. Bosma M.J., Carroll A.M. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol. 9:1991;323-350.
28. Li G., Nelsen C., Hendrickson E.A. Ku86 is essential in human somatic cells. Proc Natl Acad Sci USA. 99:2002;832-837.
29. ••].
30. ••] describe the newly identified anti-apoptotic function of Ku70, which is mediated through its interaction with Bax.
31. Nicolas N., Finnie N.J., Cavazzana-Calvo M., Papadopoulo D., Le Deist F., Fischer A., Jackson S.P., de Villartay J.P. Lack of detectable defect in DNA double-strand break repair and DNA-dependant protein kinase activity in radiosensitive human severe combined immunodeficiency fibroblasts. Eur J Immunol. 26:1996;1118-1122.
32. Nicolas N., Moshous D., Papadopoulo D., Cavazzana-Calvo M., de Chasseval R., le Deist F., Fischer A., de Villartay J.P. A human SCID condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA Recombination/Repair deficiency. J Exp Med. 188:1998;627-634.
33. Moshous D., Li L., de Chasseval R., Philippe N., Jabado N., Cowan M.J., Fischer A., de Villartay J.P. A new gene involved in DNA double-strand break repair and V(D)J recombination is located on human chromosome 10p. Hum Mol Genet. 9:2000;583-588.
34. Moshous D., Callebaut I., de Chasseval R., Corneo B., Cavazzana-Calvo M., Le Deist F., Tezcan I., Sanal O., Bertrand Y., Philippe N.et al. ARTEMIS, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell. 105:2001;177-186.
35. Li L., Moshous D., Zhou Y., Wang J., Xie G., Salido E., Hu D., de Villartay J.P., Cowan M.J. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking native americans. J Immunol. 168:2002;6323-6329.
36. Noordzij J.G., Verkaik N.S., van der Burg M., van Veelen L.R., de Bruin-Versteeg S., Wiegant W., Vossen J.M., Weemaes C.M., de Groot R., Zdzienicka M.Z.et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood. 101:2003;1446-1452.
37. Kobayashi N., Agematsu K., Sugita K., Sako M., Nonoyama S., Yachie A., Kumaki S., Tsuchiya S., Ochs H.D., Fukushima Y.et al. Novel Artemis gene mutations of radiosensitive severe combined immunodeficiency in Japanese families. Hum Genet. 112:2003;348-352.
38. Aravind L. An evolutionary classification of the metallo-β -lactamase fold. In Silico Biology. 1:1999;69-91.
39. Callebaut I., Moshous D., Mornon J.P., De Villartay J.P. Metallo-β-lactamase fold within nucleic acids processing enzymes: the β-CASP family. Nucleic Acids Res. 30:2002;3592-3601 This paper describes a new protein domain (βCASP), which is always appended to the metallo-β-lactamase domain in proteins of this family that acts on nucleic acids.
40. Ma Y., Pannicke U., Schwarz K., Lieber M.R. Hairpin opening and overhang processing by an Artemis/DNA-dependant protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell. 108:2002;781-794 This is the first demonstration of the association and phosphorylation of Artemis by DNA-PKcs. This complex then acquires the capacity of opening Rag1/2-generated hairpins.
41. Rooney S., Sekiguchi J., Zhu C., Cheng H.L., Manis J., Whitlow S., DeVido J., Foy D., Chaudhuri J., Lombard D.et al. Leaky scid phenotype associated with defective V(D)J coding end processing in artemis-deficient mice. Mol Cell. 10:2002;1379-1390 The phenotype of Artemis KO mice is mostly superimposable to that of RS-SCID patients with the interesting difference of a few emerging T lymphocytes in some mice. This suggests that an alternative nuclease activity may replace, to some extent, the Artemis deficiency in mice.
42. Barnes D.E., Stamp G., Rosewell I., Denzel A., Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryonic mice. Curr Biol. 31:1998;1395-1398.
43. Gao Y., Sun Y., Frank K.M., Dikkes P., Fujiwara Y., Seidl K.J., Sekiguchi J.M., Rathbun G.A., Swat W., Wang J.et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell. 95:1998;891-902.
44. Frank K.M., Sekiguchi J.M., Seidl K.J., Swat W., Rathbun G.A., Cheng H.L., Davidson L., Kangaloo L., Alt F.W. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature. 396:1998;173-177.
45. Riballo E., Critchlow S.E., Teo S.H., Doherty A.J., Priestley A., Broughton B., Kysela B., Beamish H., Plowman N., Arlett C.F.et al. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr Biol. 9:1999;699-702.
46. Riballo E., Doherty A.J., Dai Y., Stiff T., Oettinger M.A., Jeggo P.A., Kysela B. Cellular and biochemical impact of a mutation in DNA ligase IV conferring clinical radiosensitivity. J Biol Chem. 276:2001;31124-31132.
47. O'Driscoll M., Cerosaletti K.M., Girard P.M., Dai Y., Stumm M., Kysela B., Hirsch B., Gennery A., Palmer S.E., Seidel J.et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell. 8:2001;1175-1185.
48. Vanasse G.J., Concannon P., Willerford D.M. Regulated genomic instability and neoplasia in the lymphoid lineage. Blood. 94:1999;3997-4010.
49. Bernard O., Larsen C.J., Hampe A., Mauchauffe M., Berger R., Mathieu-Mahul D. Molecular mechanisms of a t(8;14)(q24;q11) translocation juxtaposing c-myc and TcR-alpha genes in a T-cell leukaemia: involvement of a V alpha internal heptamer. Oncogene. 2:1988;195-200.
50. Wyatt R.T., Rudders R.A., Zelenetz A., Delellis R.A., Krontiris T.G. BCL2 oncogene translocation is mediated by a chi-like consensus. J Exp Med. 175:1992;1575-1588.
51. Cayuela J.M., Gardie B., Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood. 90:1997;3720-3726.
52. Raghavan S.C., Kirsch I.R., Lieber M.R. Analysis of the V(D)J recombination efficiency at lymphoid chromosomal translocation breakpoints. J Biol Chem. 276:2001;29126-29133.
53. Ferguson D.O., Alt F.W. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene. 20:2001;5572-5579.
54. Kinzler K.W., Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 386:1997;761-763.
55. ••].
56. -/- mice to show that they are not simple balanced translocations, but rather involve complex translocation and gene amplification events (complicons).
57. Sharpless N.E., Ferguson D.O., O'Hagan R.C., Castrillon D.H., Lee C., Farazi P.A., Alson S., Fleming J., Morton C.C., Frank K.et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell. 8:2001;1187-1196.
58. Rooney S., Alt F.W., Lombard D., Whitlow S., Eckersdorff M., Fleming J., Fugmann S., Ferguson D.O., Schatz D.G., Sekiguchi J. Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J Exp Med. 197:2003;553-565.
59. Moshous D., Pannetier C., de Chasseval R., le Deist F., Cavazzana-Calvo M., Romana S., Macintyre E., Canioni D., Brousse N., Fischer A.et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest. 111:2003;381-387 This study provides the first evidence that Artemis deficiency can be accompanied with the development of B-cell lymphomas. Artemis can be considered as a genomic caretaker.
60. Dai Y., Kysela B., Hanakahi L.A., Manolis K., Riballo E., Stumm M., Harville T.O., West S.C., Oettinger M.A., Jeggo P.A. Nonhomologous end joining and V(D)J recombination require an additional factor. Proc Natl Acad Sci USA. 100:2003;2462-2467 The authors of this paper suggest that there are still new V(D)J recombination factors to be identified.
61. Nolan P.M., Peters J., Strivens M., Rogers D., Hagan J., Spurr N., Gray I.C., Vizor L., Brooker D., Whitehill E.et al. A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse. Nat Genet. 25:2000;440-443.
62. Hrabe de Angelis M.H., Flaswinkel H., Fuchs H., Rathkolb B., Soewarto D., Marschall S., Heffner S., Pargent W., Wuensch K., Jung M.et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet. 25:2000;444-447.
63. Nelms K.A., Goodnow C.C. Genome-wide ENU mutagenesis to reveal immune regulators. Immunity. 15:2001;409-418.
64. Patton E.E., Zon L.I. The art and design of genetic screens: zebrafish. Nat Rev Genet. 2:2001;956-966.
65. Langenau D.M., Traver D., Ferrando A.A., Kutok J.L., Aster J.C., Kanki J.P., Lin S., Prochownik E., Trede N.S., Zon L.I.et al. Myc-induced T cell leukemia in transgenic zebrafish. Science. 299:2003;887-890 The zebrafish is a model of choice for the analysis of the physiopathology of the immune system.